

Supplemental data

Fig S1. Transfection efficiency of hCaMKIIN β in HO-8910PM human ovarian cancer cells.

HO-8910PM cells were transfected with hCaMKIIN β for 24 h. Cells were harvested, fixed with 4% Paraformaldehyde, permeabilized with perm (Biolegend) and labeled by anti-His antibody (New England Biolabs).

Fig S2. hCaMKIIN β inhibits human ovarian cancer cell proliferation through suppression of endogenous CaMKII activity.

HO-8910PM cells were treated with KN-62 (Calbiochem, 10 μ M) for 5 h and then transfected with hCaMKIIN β or mock vector and cultured for 48h. Cell Proliferation was determined by MTT assay. *Bars*, SE.

Fig S3. Detection of hCaMKIIN β -induced apoptosis in HO-8910PM cells by transmission electron microscopy analysis. Stably transfected HO-8910PM cells were cultured for 48 h and then were visualized under transmission electron microscopy. Bar=5 μ m.

Fig S4. Quantification of hCaMKIIN β -induced target protein expression in HO-8910PM human ovarian cancer cells.

HO-8910PM cells were collected 24, 48, and 72h post-transfection with hCaMKIIN β for Western blot analysis with the indicated antibodies. A, p53 expression in Fig. 6A was performed quantitative analysis. B, p-Akt (left) and p-HDM2 (right) expression in Fig. 6B was performed quantitative analysis. *, $P < 0.01$ vs. mock.

Fig S5. Assay for OVCAR-3 human ovarian cancer cell proliferation by MTT assay.

OVCAR-3 cells were transfected with pKIIN β or mock vectors, and then stable transfectants were obtained by G418 selection. The expression of hCaMKIIN β was confirmed by Western blot analysis using anti-hCaMKIIN β polyclonal antibody. An 11-kDa protein band was prominent in hCaMKIIN β -transfected cells but not in mock-transfected or parental cells. The proliferation of stably transfected OVCAR-3 cells was examined by MTT assay. *Bars*, SE.

Figure S1




Figure S2




Figure S3




Figure S4




Figure S5

